CIAM
IPHA

Caitong International Asset Management’s Innate Pharma IPHA Stock Holding History

Caitong International Asset Management’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$3 – 3218
2026
Q1 		$3 Buy
+2
New +$3 ﹤0.01% 2381

Other funds holding IPHA

LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Caitong International Asset Management's IPHA Position: Q2 2026 in Review

Caitong International Asset Management sold out of Innate Pharma (IPHA) in Q2 2026, closing a stake of 2 shares — an estimated $3 sold.

Caitong International Asset Management first reported a position in IPHA in Q1 2026 and held it in 1 quarter. The position peaked at $3 in Q1 2026. 10 funds tracked by Wall St. Rank hold IPHA as of Q2 2026.

  • Caitong International Asset Management reported no remaining Innate Pharma position as of Q2 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 2 Innate Pharma shares in Q2 2026, an estimated $3.
  • Caitong International Asset Management first reported a position in Innate Pharma in Q1 2026 and held it in 1 quarter.
  • Caitong International Asset Management's Innate Pharma position peaked at $3 in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.